Recent clinical evidence suggests that Novera Retatrutide, a combined-action therapy from Novo Nordisk, could represent a meaningful breakthrough in weight control. Unlike many existing drugs, Retatrutide targets both glucagon-like peptide-1 (GLP-1) and the GIP hormone, potentially producing to g